Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375199 | 0.83 | PPARG (0.41) | PPARGGPR132MEN1KMT2ALTB4R | |
| SCHEMBL27211828 | 0.83 | PPARG (0.40) | PPARGGPR132MEN1KMT2ALTB4R | |
| SCHEMBL27211914 | 0.83 | PPARG (0.40) | PPARGGPR132MEN1KMT2ALTB4R | |
| SCHEMBL27211781 | 0.83 | PPARG (0.40) | PPARGGPR132MEN1KMT2ALTB4R | |
| SCHEMBL27211937 | 0.83 | PPARG (0.43) | PPARGGPR132MEN1KMT2ALTB4R | |
| SCHEMBL27211716 | 0.83 | PPARG (0.40) | PPARGGPR132MEN1KMT2ALTB4R | |
| SCHEMBL21483857 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TSHRFASNCNR1CNR2 | |
| SCHEMBL21484030 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TSHRFASNCNR1CNR2 | |
| SCHEMBL21483936 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TSHRFASNCNR1CNR2 | |
| SCHEMBL21491092 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TSHRFASNCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4365159-B1 | ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND | SHINETSU CHEMICAL CO (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20240174701-A1 | ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4365159-A1 | ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND | Shin-Etsu Chemical Co., Ltd. (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117924017-A | Organic halogen compound having conjugated double bond, method for preparing acetate and alcohol derivative thereof, and compound for synthesizing the compound | 信越化学工业株式会社 | 2024-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174701-A1 | ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND | ADH5, ADH1C, ADH1A | PPARG 104/4885GPR132 1507/4885MEN1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.